Proprietary AI analyst is now available

Ginkgo Bioworks Valuation Multiples

Discover Ginkgo Bioworks' revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Grupa Azoty, Gujarat State Fertilizers, Intrepid Potash, SunOpta and more.

Ginkgo Bioworks Overview

About Ginkgo Bioworks

Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.


Founded

2008

HQ

United States

Employees

834

Financials (LTM)

Revenue: $140M
EBITDA: ($169M)

EV

$636M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Ginkgo Bioworks Financials

Ginkgo Bioworks reported last 12-month revenue of $140M and negative EBITDA of ($169M).

In the same LTM period, Ginkgo Bioworks generated $94M in gross profit, ($169M) in EBITDA losses, and had net loss of ($313M).

Revenue (LTM)


Ginkgo Bioworks P&L

In the most recent fiscal year, Ginkgo Bioworks reported revenue of $170M and EBITDA of ($167M).

Ginkgo Bioworks is unprofitable as of last fiscal year, with gross margin of 72%, EBITDA margin of (98%), and net margin of (184%).

See analyst estimates for Ginkgo Bioworks
LTMLast FY202320242025202620272028
Revenue$140M$170M$251M$227M$170M
Gross Profit$94M$123M$197M$182M$123M
Gross Margin67%72%79%80%72%
EBITDA($169M)($167M)($821M)($484M)($255M)
EBITDA Margin(121%)(98%)(327%)(213%)(150%)
EBIT Margin(194%)(179%)(306%)(215%)(179%)
Net Profit($313M)($313M)($893M)($547M)($313M)
Net Margin(224%)(184%)(355%)(241%)(184%)

Financial data powered by Morningstar, Inc.

Ginkgo Bioworks Stock Performance

Ginkgo Bioworks has current market cap of $599M, and enterprise value of $636M.

Market Cap Evolution


Ginkgo Bioworks' stock price is $9.17.

Ginkgo Bioworks share price decreased by 2.1% in the last 30 days, and by 18.5% in the last year.

Ginkgo Bioworks has an EPS (earnings per share) of $-4.79.

See more trading valuation data for Ginkgo Bioworks
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$636M$599M0.0%-2.1%49.6%-18.5%$-4.79

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Ginkgo Bioworks Valuation Multiples

Ginkgo Bioworks trades at 4.6x EV/Revenue multiple, and (3.8x) EV/EBITDA.

See NTM and 2027E valuation multiples for Ginkgo Bioworks

EV / Revenue (LTM)


Ginkgo Bioworks Financial Valuation Multiples

As of June 22, 2026, Ginkgo Bioworks has market cap of $599M and EV of $636M.

Ginkgo Bioworks has a P/E ratio of (1.9x).

LTMLast FY202320242025202620272028
EV/Revenue4.6x3.7x2.5x2.8x3.7x
EV/EBITDA(3.8x)(3.8x)(0.8x)(1.3x)(2.5x)
EV/EBIT(2.3x)(2.1x)(0.8x)(1.3x)(2.1x)
EV/Gross Profit6.8x5.2x3.2x3.5x5.2x
P/E(1.9x)(1.9x)(0.7x)(1.1x)(1.9x)
EV/FCF-(3.6x)(1.9x)(1.7x)(3.6x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Ginkgo Bioworks Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Ginkgo Bioworks Margins & Growth Rates

Ginkgo Bioworks decreased revenue by 38% but EBITDA grew by 3% in the last fiscal year.

In the most recent fiscal year, Ginkgo Bioworks reported gross margin of 72%, EBITDA margin of (98%), and net margin of (184%).

See estimated margins and future growth rates for Ginkgo Bioworks

Ginkgo Bioworks Margins

Last FY202420252026202720282029
Gross Margin72%80%72%-
EBITDA Margin(98%)(213%)(150%)(163%)
EBIT Margin(179%)(215%)(179%)(211%)
Net Margin(184%)(241%)(184%)-
FCF Margin(105%)(168%)(105%)-

Ginkgo Bioworks Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(38%)(10%)(25%)(38%)
Gross Profit Growth-(8%)(33%)-
EBITDA Growth3%(41%)(47%)(32%)
EBIT Growth(27%)(37%)(38%)(27%)
Net Profit Growth-(39%)(43%)-
FCF Growth-14%(53%)-

Data powered by FactSet, Inc. and Morningstar, Inc.

Ginkgo Bioworks Operational KPIs

Ginkgo Bioworks' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.5M for the same period.

Ginkgo Bioworks' Rule of 40 is (201%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Ginkgo Bioworks' Rule of X is (257%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Ginkgo Bioworks
LTMLast FY202320242025202620272028
Rule of 40(142%)(201%)---
Bessemer Rule of X(173%)(257%)---
Revenue per Employee-$0.2M---
Opex per Employee-$0.5M---
G&A Expenses to Revenue107%108%153%108%108%
R&D Expenses to Revenue171%143%231%187%143%
Opex to Revenue-251%384%295%251%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Ginkgo Bioworks Competitors

Ginkgo Bioworks competitors include Grupa Azoty, Gujarat State Fertilizers, Intrepid Potash, SunOpta, Anhui Huaheng, Itafos, Takara Bio, Biotest, Cabio Biotech (Wuhan) Co and Codexis.

Most Ginkgo Bioworks public comparables operate across Bioindustrials, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Grupa Azoty0.9x0.9x40.2x18.0x
Gujarat State Fertilizers0.5x-4.8x-
Intrepid Potash1.2x1.4x6.0x6.2x
SunOpta----
Anhui Huaheng2.5x2.3x17.1x13.0x
Itafos0.7x0.6x2.1x2.8x
Takara Bio2.9x3.2x20.3x-
Biotest----

This data is available for Pro users. Sign up to see all Ginkgo Bioworks competitors and their valuation data.

Start Free Trial

Ginkgo Bioworks VC Funding History

Before going public, Ginkgo Bioworks raised $798M in total equity funding, across 7 rounds.

Last private valuation of Ginkgo Bioworks was $4B, after raising $290M in September 2019 from Meros Equity Global Management, T. Rowe Price, Cascade Investment, and 2 other investors.


Ginkgo Bioworks Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
May-20Series FGeneral Atlantic; Illumina; Viking Global Investors; Empede Capital$70M-Ginkgo Bioworks raised $70 million on May 28, 2020, from investors including Empede Capital, General Atlantic, Illumina, and Viking Global Investors to build infrastructure for rapid epidemic response. The company operates a cell programming platform enabling biotechnology applications across markets like food, agriculture, industrial chemicals, and pharmaceuticals, while also supporting biosecurity efforts such as COVID-19 vaccine optimization and testing. For the fiscal year ended December 31, 2020, Ginkgo Bioworks reported total revenue of $76.66 million, up 41.48% from $54 million in 2019. This figure captures activity around the time of the funding, reflecting growth in its synthetic biology services. The company had net losses, with a 2020 net loss of approximately $127 million based on quarterly data leading into year-end. Subsequent years showed revenue scaling to $313.84 million in 2021 and peaking at $477.71 million in 2022 driven by biosecurity and foundry segments, before declining.
Sep-19Series EMeros Equity Global Management; T. Rowe Price; Cascade Investment; General Atlantic; Viking Global Investors$290M$4BGinkgo Bioworks, a Boston-based synthetic biology company founded in 2008 and launched through Y Combinator, raised $290 million in its Series E funding round in September 2019, achieving a $4 billion post-money valuation and bringing total funding to $719 million. The round included participation from existing major investors such as Cascade Investment, General Atlantic, and Viking Global Investors, along with new investors including funds advised by T. Rowe Price Associates and Meros Equity Global Management. Proceeds were earmarked to expand the reach of Ginkgo's cell programming platform, which enables the creation of custom microbes using automation for applications in materials, clothing, electronics, food, pharmaceuticals, and more, positioning biology as a manufacturing alternative. This funding followed a $275 million Series D in Q4 2017 that valued the company over $1 billion, funding the construction of its Bioworks3 production site. By 2019, Ginkgo had secured major partnerships including a $122 million deal with Cronos for cultured cannabinoids, up to $160 million with Roche for novel antibiotics, and an $80 million investment in Synlogic for living medicines. The company also launched spinouts like Motif FoodWorks with $117 million for alternative proteins and Joyn Bio for sustainable agriculture, while establishing programs with Y Combinator and Petri to support early-stage biotech startups using its platform in exchange for equity. The Series E made Ginkgo Bioworks Boston's most valuable venture-backed company at the time, with founders' stakes estimated at $250 million each.
Dec-17Series Dbpd partners; Y Combinator; Bill Gates; Cascade Investment; General Atlantic; Viking Global Investors$275M$1BGinkgo Bioworks, a Boston-based synthetic biology company founded in 2008 by five MIT scientists, designs and manufactures genetically engineered microbes for commercial applications across multiple industries. The company uses proprietary DNA design software and robotic fermentation infrastructure to reprogram microbe genomes according to client specifications. Its core offerings include cultured ingredients for perfumes, cosmetics, and food; strain improvement for fermentation-based bioindustrial applications; and enzymes for uses ranging from cheesemaking to pharmaceuticals. Notable clients include Robertet (peach fragrance synthesis), the U.S. Department of Defense (probiotics for soldier health), ADM, Cargill, Ajinomoto, Kerry, and Swissaustral. On December 14, 2017, Ginkgo Bioworks announced a $275 million Series D funding round led by returning investors Viking Global, Y Combinator's Continuity Fund, Cascade Investment (William H. Gates III's vehicle), and Bill Gates, alongside new investor General Atlantic. This round brought the company's total cumulative funding to $429 million and achieved "unicorn" status with a post-money valuation exceeding $1 billion, making it the second agtech unicorn in Boston after Indigo Agriculture. The capital was earmarked for expanding Ginkgo's infrastructure and entering new markets. The company announced the opening of Bioworks3, a 17,000 square-foot robotic microbe foundry that increased total Boston facility space to 74,000 square feet, with plans for Bioworks4 and Bioworks5. In the same period, Ginkgo had acquired Gen9 (synthetic DNA printer) in January 2017, secured a $100 million joint venture with Bayer CropScience in October 2017 for agricultural applications targeting nitrogen fixation, announced a partnership with Synlogic for pharmaceutical-grade gut microbe engineering, and acquired a one billion base pair DNA supply agreement from Twist Bioscience. These initiatives positioned Ginkgo to scale its synthetic biology platform across cultured ingredients, agriculture, pharmaceuticals, and industrial fermentation sectors.
Jun-16Series CBaillie Gifford; Y Combinator; Cascade Investment; Allen & Company; Senator Investment Group; Viking Global Investors$100M$450MGinkgo Bioworks, a Boston-based organism design company, announced a $100 million Series C funding round on June 8, 2016, led by a consortium of investors including Y Combinator's Continuity Fund, Senator Investment Group, Cascade Investment, Baillie Gifford, Viking Global Investors (which also led the Series B), and Allen & Company LLC. This round brought the company's cumulative funding to $154 million since its launch from Y Combinator less than two years prior, positioning it in the top 10 most highly funded YC startups. The $100 million was primarily deployed to purchase 600 million base pairs of synthetic DNA from Twist Bioscience and Gen9, which the company claimed was the largest amount of synthetic DNA ever purchased at that time. Ginkgo used these genetic resources to expand its production capabilities and extend into new markets beyond its original focus on flavor and fragrance ingredients, targeting commodity chemicals, industrial enzymes, human health, pharma, cosmetics, and probiotics. The company operated an 18,000-square-foot biofoundry in Boston (Bioworks 1) and was constructing a second 70,000-square-foot automated facility (Bioworks 2) to begin operations in Q3 2016, leveraging software and robotics to engineer microbes that produced specialty chemicals for customer partners.
Jul-15Series BKen Arnold; Y Combinator; iD Ventures America; Felicis; Vast Ventures; 11.2 Capital; DCVC; iGlobe Partners; OS Fund; Viking Global Investors; MassVentures$53M$200M-
Mar-15Series AFelicis; Vast Ventures; DCVC; iGlobe Partners; OS Fund$9M-Ginkgo Bioworks raised $9 million in a Series A financing round on March 19, 2015, from OS Fund, Felicis Ventures, Data Collective (DCVC), Vast Ventures, and iGlobe Partners. The company, founded in 2008 and the first biotech startup in Y Combinator's Summer 2014 class, specializes in organism engineering, designing microbes for cultured ingredients like fragrances, flavors, sweeteners, and cosmetics, as well as applications in chemicals, fuels, probiotics, and natural product discovery. The funds supported the operation of Bioworks1, an 18,000-square-foot automated foundry with robotics and software for scalable organism engineering, and initial planning for Bioworks2 in 2017. Prior to the round, Ginkgo secured over $15 million in contracts from DARPA and other government agencies for foundry technology development. The company had completed 20 organism design contracts with Fortune 500 customers, where clients order R&D and share royalties upon production. Investors highlighted Ginkgo's potential to revolutionize biology engineering like software, addressing challenges in healthcare, energy, and beyond.
Jul-14SeedKen Cheng; Ken Arnold; Azure Capital Partners; Y Combinator; Felicis; Four Cities Capital; David Spector; Arda Kutsal; TSVC; 11.2 Capital; Jonathan Downey; Farzad Nazem$1M--

Acquisitions by Ginkgo Bioworks

Ginkgo Bioworks has acquired 15 companies to date.

Last acquisition by Ginkgo Bioworks was on April 11th 2024. Ginkgo Bioworks acquired AgBiome (The GENESIS unit) for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by Ginkgo Bioworks

AgBiome (The GENESIS unit)
Modulus Therapeutics (cell therapy platform unit)
Proof Diagnostics
Reverie Labs
Description
AgBiome's GENESIS unit is a microbial discovery platform based in Research Triangle Park, North Carolina, curating one of the world's largest collections of plant-associated microbes. It screens billions of microbes annually to identify novel bioactives for crop protection, personal care, and industrial applications. The unit licenses strains to partners developing sustainable ingredients free of synthetic chemicals.
Modulus Therapeutics (cell therapy platform unit) is a Boston-based biotechnology entity developing libraries of chimeric antigen receptor designs and switch receptors for next-generation cell therapies. The platform targets solid tumors and hematologic malignancies, enabling tunable CAR-T therapies with enhanced safety profiles. Modulus Therapeutics licenses these assets to partners in the immuno-oncology space.
Proof Diagnostics is a biotechnology firm developing portable diagnostic devices for infectious diseases using computational discovery platforms. Headquartered in the United States, it advances point-of-care tests for pathogens like COVID-19 and malaria, integrating CRISPR-based detection with smartphone connectivity to enable rapid results in remote settings.
Reverie Labs is a San Francisco-headquartered biotech firm using machine learning for small-molecule drug discovery in oncology and neurology. As a Y Combinator Winter 2018 company, Reverie Labs applies generative models to optimize lead compounds reducing preclinical timelines. The team generates novel chemical structures screened via in silico assays against protein targets. Reverie Labs partners with CROs for synthesis and holds patents on AI-optimized inhibitors.
HQ CountryUnited StatesUnited StatesUnited StatesUnited States
HQ City
Raleigh, NC
Seattle, WA
-
-
Deal Date11 Apr 20242 Apr 202428 Feb 202428 Feb 2024
Valuationundisclosedundisclosedundisclosed$4M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Ginkgo Bioworks acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Ginkgo Bioworks

Ginkgo Bioworks has invested in 5 companies to date.

Latest investment by Ginkgo Bioworks was on July 5th 2022. Ginkgo Bioworks invested in Phytolon in their $15M Series A round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Ginkgo Bioworks

Phytolon
Cambium
Allonnia
Genomatica
Description
Phytolon is a Lund-based biotechnology company that ferments yeast strains to produce natural carotenoids including astaxanthin and beta-carotene for food coloring. Its microbial production process replaces synthetic dyes and chemical extraction from plants, targeting beverages, dairy, and confectionery products. Phytolon partners with global food ingredient suppliers to scale manufacturing in Europe. The firm holds patents on genetically engineered yeasts optimized for high-yield pigment secretion in fermenters.
Cambium is a Boston-based deep tech company engineering biomaterials from fungal mycelium for defense armor, aerospace components, and renewable energy panels. Founded in 2020, it combines synthetic biology with automation to produce leather alternatives stronger than Kevlar. Cambium supplies prototypes to DARPA and NASA programs.
Allonnia is a biotechnology firm developing microbial solutions for environmental remediation, waste upcycling, and carbon capture. Based in Boston, Massachusetts, the company engineers bacteria to treat contaminated water, restore mining sites, and convert industrial waste into valuable products like biofuels. Allonnia's platform has been deployed at Superfund sites and mining operations in the United States and South America. Named a finalist in Fast Company's 2023 Next Big Things in Tech for its BioAir product, which reduces methane emissions from landfills, Allonnia raised $35 million in Series A funding in 2023. The firm partners with mining giants and wastewater utilities to lower CO2 footprints and achieve regulatory compliance.
Genomatica is a San Diego-based company engineering biobased technologies for chemical production from renewable feedstocks. It has commercialized processes for 1,4-butanediol used in biodegradable plastics and apparel, and butylene glycol for cosmetics via its Brontide product. The firm pursues bio-nylon and has received the Kirkpatrick Award and ICIS Innovation Award for its advancements.
HQ CountryIsraelUnited StatesUnited StatesUnited States
HQ City
Yokneam Illit
Mojave, CA
Boston, MA
San Diego, CA
Deal Date5 Jul 202214 Sep 202122 Oct 20203 Oct 2018
RoundSeries ASeedSeries AUndisclosed stage
Raised$15M$8M$40M$90M
InvestorsCibus Fund; Ginkgo Bioworks; OpenValley; Agriline; Arkin Holdings; Trendlines Group; DSM Venturing; Stern Tech; Millenium Food-Tech; Yossi AckermanGinkgo Bioworks; 8VCBattelle; Ginkgo Bioworks; Cascade Investment; General Atlantic; Viking Global InvestorsGinkgo Bioworks; Casdin Capital; Viking Global Investors
Valuationundisclosedundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Ginkgo Bioworks investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Ginkgo Bioworks

When was Ginkgo Bioworks founded?Ginkgo Bioworks was founded in 2008.
Where is Ginkgo Bioworks headquartered?Ginkgo Bioworks is headquartered in United States.
How many employees does Ginkgo Bioworks have?As of today, Ginkgo Bioworks has over 834 employees.
Who is the CEO of Ginkgo Bioworks?Ginkgo Bioworks' CEO is Jason Kelly.
Is Ginkgo Bioworks publicly listed?Yes, Ginkgo Bioworks is a public company listed on NYSE.
What is the stock symbol of Ginkgo Bioworks?Ginkgo Bioworks trades under DNA ticker.
When did Ginkgo Bioworks go public?Ginkgo Bioworks went public in 2021.
Who are competitors of Ginkgo Bioworks?Ginkgo Bioworks main competitors include Grupa Azoty, Gujarat State Fertilizers, Intrepid Potash, SunOpta, Anhui Huaheng, Itafos, Takara Bio, Biotest, Cabio Biotech (Wuhan) Co, Codexis.
What is the current market cap of Ginkgo Bioworks?Ginkgo Bioworks' current market cap is $599M.
What is the current revenue of Ginkgo Bioworks?Ginkgo Bioworks' last 12 months revenue is $140M.
What is the current revenue growth of Ginkgo Bioworks?Ginkgo Bioworks revenue growth (NTM/LTM) is (21%).
What is the current EV/Revenue multiple of Ginkgo Bioworks?Current revenue multiple of Ginkgo Bioworks is 4.6x.
Is Ginkgo Bioworks profitable?No, Ginkgo Bioworks is not profitable.
What is the current EBITDA of Ginkgo Bioworks?Ginkgo Bioworks has negative EBITDA and is not profitable.
What is Ginkgo Bioworks' EBITDA margin?Ginkgo Bioworks' last 12 months EBITDA margin is (121%).
What is the current EV/EBITDA multiple of Ginkgo Bioworks?Current EBITDA multiple of Ginkgo Bioworks is (3.8x).
How many companies Ginkgo Bioworks has acquired to date?As of June 2026, Ginkgo Bioworks has acquired 15 companies.
What was the largest acquisition by Ginkgo Bioworks?$300M acquisition of Zymergen on 25th July 2022 was the largest M&A Ginkgo Bioworks has done to date.
What companies Ginkgo Bioworks acquired?Ginkgo Bioworks acquired Zymergen, Warp Drive Bio, FGen, Circularis Biotechnologies, Patch Biosciences, Altar, Reverie Labs, Bitome, Proof Diagnostics, AgBiome (The GENESIS unit), and 5 other companies.
In how many companies Ginkgo Bioworks has invested to date?As of June 2026, Ginkgo Bioworks has invested in 5 companies.
In what companies Ginkgo Bioworks invested in?Ginkgo Bioworks invested in Joyn Bio, Genomatica, Allonnia, Phytolon, and Cambium.

See public comps similar to Ginkgo Bioworks

Lists including Ginkgo Bioworks

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial